| Document |
Document Title |
|
WO/2024/102587A2 |
The disclosure provides engineered interleukin 18 (IL-18) polypeptides with reduced binding to IL-18 binding protein (IL-18BP) and maintained or improved binding to one or both of IL-18 Receptor alpha (IL-18Rα) and IL-18 Receptor beta (...
|
|
WO/2024/099103A1 |
A polypeptide having an analgesic effect and a use thereof. The polypeptide or a construct thereof can be used as a positive allosteric modulator and used in combination with a TRPV1 receptor agonist to enhance an agonistic effect on TRP...
|
|
WO/2024/100549A1 |
The present invention relates to compounds for use for treating and/or preventing tumors by virtue of the ability to reprogram tumor-associated macrophages M2 (TAM-M2) to tumor-associated macrophages M1 (TAM-M1).
|
|
WO/2024/102860A1 |
Strategies, systems, compositions, and methods for genetically modifying cells to include one or more loss-of-function modifications and/or to include one or more gain-of-function modifications, as well as modified cells (and composition...
|
|
WO/2024/098496A1 |
Provided are an enzyme composition and use thereof. The enzyme composition consists of β-1,3-glucanase and glucose oxidase, wherein the mass ratio of the β-1,3-glucanase to the glucose oxidase is (5-80):(30-500). The enzyme composition...
|
|
WO/2024/102941A1 |
Provided herein are engineered IL- 15 (eIL-15) molecules and complexes containing engineered IL-15 molecules (eIL-15 complexes) and encoding polynucleotides. Also provided are compositions and articles of manufacture containing the conju...
|
|
WO/2024/102633A1 |
An insulin conjugate comprising or consisting of a penta-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the system...
|
|
WO/2023/230566A9 |
The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors or host cells, that comprise and/or modulate expression or activity of immune regulation...
|
|
WO/2024/101386A1 |
The present inventors found a cyclic compound that selectively inhibits KRAS. The present inventors also found that the cyclic compound interacts with a KRAS-specific amino acid residue.
|
|
WO/2024/098967A1 |
The present invention provides use of an N-terminus kinase inhibitor SU3327 of C-JUN in preparing a drug for enhancing anti-bacterial-infection efficacy of polymyxin and use of a composition of the SU3327 and the polymyxin in preparing a...
|
|
WO/2024/102973A1 |
Described are compositions, methods, systems, and kits related to related to synthetic phages with a customized host range. Customized host range of the synthetic phage is imparted on the synthetic phage by one or more recombinant tail-s...
|
|
WO/2024/102997A1 |
The present invention discloses methods to prevent gout flares using IL-1β inhibitors. A method of treating gout patients using methotrexate, canakinumab, and pegloticase is described.
|
|
WO/2024/098127A1 |
The present invention describes nanostructured lipid systems containing the antibiotic besifloxacin and the application thereof in the treatment and prevention of bacterial eye infections. Besifloxacin, an antibiotic with low aqueous sol...
|
|
WO/2024/064200A3 |
The present disclosure provides compositions comprising a designed ankyrin repeat protein (DARPin) for use in treating Shiga toxin (Stx)-producing Escherichia coli (STEC) and related diseases, including hemolytic uremic syndrome (HUS). T...
|
|
WO/2024/100219A1 |
The present invention relates to an active ingredient consisting of the following molecules: acetic acid, butyric acid, lactic acid and propionic acid, and/or a salt and/or an ester and/or an anhydride of one or more of these molecules, ...
|
|
WO/2024/073622A3 |
Provided herein are radiopharmaceutical conjugate compositions targeting EphA2 and uses thereof. In one aspect, provided herein are conjugates that comprise a peptide with avidity to EphA2 and a metal chelator configured to bind with a r...
|
|
WO/2024/100548A1 |
The present invention relates to the medical use of a compound in the treatment of tumor metastases.
|
|
WO/2024/102906A2 |
The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain or moiety. The invention also features p...
|
|
WO/2024/102796A2 |
Embodiments of the present disclosure generally relate to the stabilization of biologics, such as blood clotting factors, in a dry state. Methods and compositions for stabilizing biologics are described and can include an intrinsically d...
|
|
WO/2024/102466A2 |
The present disclosure provides certain IgA protease polypeptide agents, and uses therefore, including, in some embodiments cleaving IgAl present in deposits in vivo.
|
|
WO/2024/076499A3 |
The technology described herein is directed to stromal-free methods of T cell differentiation using a soluble Notch ligand. Also described herein are soluble Notch oligomer complexes and compositions thereof, and methods for making the s...
|
|
WO/2024/102345A1 |
Methods are provided for preventing post-operative atrial fibrillation by administering a botulinum toxin to epicardial fat pads in the heart of a patient.
|
|
WO/2024/099445A1 |
A site-specific PEGylated heteromeric protein or polypeptide, and a preparation method therefor and the use thereof. Firstly, provided is a method for the site-specific PEGylation of a protein or polypeptide. The method comprises providi...
|
|
WO/2024/102986A2 |
The present disclosure relates to certain molecules, pharmaceutical compositions containing them, and methods of using them to treat viral infections.
|
|
WO/2024/102077A1 |
Compounds, compositions, uses, and methods for reducing obesity in a subject, or for preventing or treating obesity, are provided herein. In certain examples, methods for reducing obesity in a subject and/or for preventing or treating ob...
|
|
WO/2024/103042A1 |
The present disclosure is related to improved compositions and methods related to viral immunotherapy treatments for cancer. Specifically, provided herein are therapeutic rAAV vectors, particles, and compositions thereof related to treat...
|
|
WO/2023/166284A8 |
The present invention provides uses of enzymes for cleaving a linkage between two D- galactofuranoses and/or two D-arabinofuranoses in a polysaccharide. An example of a polysaccharide where such linkages are present is arabinogalactan. T...
|
|
WO/2024/103022A1 |
Disclosed are methods for encapsulating pH sensitive cargos, including oxygen binding proteins, in a polydopamine shell.
|
|
WO/2024/102838A1 |
The present disclosure provides engineered interleukin-7 (IL-7) receptors, and fragments and derivatives thereof, particularly IL-7 receptor alpha chain (IL-7Rα) polypeptides comprising one or more mutations, for example, in the IL-7Rα...
|
|
WO/2024/102634A1 |
The present disclosure relates to methods of treating, preventing, or managing a cardiovascular and/or metabolic disorder in a human subject in need thereof by administering a human FGF21 protein variant, the metabolic disorder and/or ca...
|
|
WO/2024/040220A3 |
Therapeutics which target CD83 show great promise in the treatment and prevention of cancer and immunological disorders. The disclosure provides a fusion protein comprising a CD83 binding domain comprising the amino acid sequences of SEQ...
|
|
WO/2024/098383A1 |
Disclosed are a protein mutant with a sequence having more than 80% identity to SEQ ID NO. 1, a gRNA used in combination with the protein mutant, a gene editing system, an expression vector, a modified cell, a pharmaceutical composition,...
|
|
WO/2024/100392A1 |
The present invention provides novel drug-inducible degradation tags (degrons), as well as fusion proteins, cells and pharmaceutical compositions comprising the same. Nucleic acid sequences and vectors encoding the novel degrons are also...
|
|
WO/2024/101935A1 |
The present invention relates to an amphiphilic conjugate comprising a self-assemblyable peptide and use thereof. A conjugate according to one aspect and a pharmaceutical composition comprising same can be useful in the prevention or tre...
|
|
WO/2024/102639A1 |
The disclosure provides the development of enantiomer-specific 7V-arylpyrazole dipeptides as novel N0D2 agonists which are effective at promoting immune checkpoint inhibitor therapy requiring N0D2 for activity. Given the significant func...
|
|
WO/2024/050372A3 |
The present invention relates to lipid nanoparticle (LNP) compositions, and therapeutic polynucleotides, e.g. TERT mRNA, which may be delivered with the LNP compositions in formulations for the prevention or treatment of lung disease and...
|
|
WO/2024/098848A1 |
The present application relates to a preparation method for a bird's nest peptide: mixing bird's nest and water, and stewing to prepare a cooked bird's nest material; homogenizing the cooked bird's nest material to prepare a bird's nest ...
|
|
WO/2024/102993A1 |
A peptide with r residues (from 4-10) that are either cationic or aromatic. The peptide has a cationic D-amino acid at the N-terminus and a cationic D-amino acid at the C-terminus. The net number of positive residues (np), is 2 ≤ np â‰...
|
|
WO/2024/100615A1 |
Nutraceutical supplement comprising or consisting of: - lactoferrin proteins, from 3.5% to 27% by weight; - bovine colostrum, from 3.5% to 27% by weight; - zinc gluconate, containing an amount from 0.25% to 2% by weight of zinc; and - vi...
|
|
WO/2024/098718A1 |
Provided are a novel long-acting polypeptide compound, a composition, and a use thereof. In the long-acting polypeptide compound, the substitution of an amino acid at a key particular position enhances the stability, activity and hydroly...
|
|
WO/2023/034793A9 |
Disclosed herein is the effect that IL-33 has on the tumor microenvironment. In one aspect, disclosed herein are methods for treating a cancer, inhibiting TH2 pro-tumorigenic cytokines in the TME, inhibiting secretion of IL-33 in the TME...
|
|
WO/2024/102865A2 |
Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods ...
|
|
WO/2024/102818A1 |
Described herein is a method of treating a human patient with a solid tumor, the method including administering to the human patient an effective amount of a fusion polypeptide comprising a tissue factor fragment and a covalently linked ...
|
|
WO/2024/099883A1 |
The present disclosure generally relates to compositions and methods to reduce the biological age and/ or reduce the rate of increase of the biological age of an adult animal. More specifically, the present disclosure relates to administ...
|
|
WO/2024/100391A2 |
The invention provides novel antibacterial compounds of formula I as defined herein. (I) The invention also provides the use of such compounds in treating or preventing bacterial infections, and processes for their synthesis.
|
|
WO/2024/099428A1 |
Provided are a membrane fusion inhibitor for inhibiting HIV and a drug-resistant strain thereof, a derivative thereof, a pharmaceutical composition thereof, and a pharmaceutical use thereof.
|
|
WO/2023/069967A8 |
Provided is a recombinant adeno-associated virus (rAAV) having an AAV capsid and a vector genome which comprises a nucleic acid sequence encoding a functional CDKL5 (hCDKLK5). Also provided are a production system useful for producing th...
|
|
WO/2024/102874A1 |
Provided herein is a method for treating cancer comprising administering to a subject having a cancer a fenofibrate (FF), fenofibric acid (FFA), an FFA prodrug, or a derivative thereof that has PPAR-a agonist activity and a T cell or T c...
|
|
WO/2024/102722A1 |
The present disclosure relates to methods of treating a tumor (or cancer) with an unmethylated MGMT promoter in a subject in need thereof. In some aspects, the method comprises administering to the subject an anti-cancer treatment, compr...
|
|
WO/2024/102995A1 |
Disclosed herein, are compositions and methods using Chlamydia Muridarum organisms in the treatment and prevention of human Chlamydia trachomatis infections in a subject. Also, disclosed herein are compositions and methods for eliciting ...
|
